article

Expert view: Optimising the hit-to-lead workflow

Hits identified in high-throughput screens are evaluated within the hit-to-lead phase of drug discovery, where they undergo an iterative optimisation process employing a variety of techniques to identify promising lead compounds to move forward to the lead optimisation phase.

Typically, the workflow starts by confirming the hits identified in the initial HTS by repeating the initial assay, as well as running orthogonal assays using different assay technologies. This may then be further triaged by screening concentration curves to evaluate relative affinities, efficacies and selectivity of the compounds to the biological target of interest.

Analogous compounds from a set with similar structural profiles to the hit compounds are tested against a variety of parameters, including toxicity, metabolic stability and solubility. These assays commonly include physiologically relevant cell based assays often in different species.

This process needs to be carried out systematically, and ideally in a relatively high-throughput manner to allow for testing of the broadest range of chemical analogues possible. Where structural information about the target is known, structure-based drug design techniques using molecular modelling and methodologies such as x-ray crystallography and NMR can also be applied to develop the SAR (structure activity relationship) faster and in a more focused way, as well as potentially identify new binding sites on the target proteins.

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

An ideal strategy for hit-to-lead optimisation should be amenable to a high-throughput format to allow for the interrogation of the widest possible chemical space to establish the optimal activity on the biological target.

TTP Labtech’s automation solutions are designed to streamline these workflows by addressing common sample management, liquid handling and assay screening bottlenecks. Our innovative technologies focus on minimising costs, eliminating laborious or problematic processes, improving data quality, and the preservation of sample integrity.

Leave a Reply

Your email address will not be published. Required fields are marked *